NBIX vs PSBD · P/E 45, rev $2.36B vs $334.2M cap
Neurocrine Biosciences Inc (NBIX) versus Palmer Square Capital BDC Inc. (PSBD) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Palmer Square Capital BDC Inc. (PSBD) is a asset management company listed on NYSE.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
PSBD does not have a complete income-statement cache yet.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. PSBD currently screens at market cap $334.2M.
Not investment advice. Open the NBIX and PSBD stock pages for the full models.
Not investment advice.